

The miRNA–target interactions: An underestimated intricacy

Caroline Diener^{1,†}, Andreas Keller^{2,3,*} and Eckart Meese^{1,†}

¹Saarland University (USAAR), Institute of Human Genetics, 66421 Homburg, Germany

²Saarland University (USAAR), Chair for Clinical Bioinformatics, 66123 Saarbrücken, Germany

³Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)–Helmholtz Centre for Infection Research (HZI), Saarland University Campus, 66123 Saarbrücken, Germany


*To whom correspondence should be addressed. Tel: +49 681 30268611; Fax: +49 681 30268616; Email: andreas.keller@ccb.uni-saarland.de

†All three authors should be considered as equal contributors.

Abstract

MicroRNAs (miRNAs) play indispensable roles in posttranscriptional gene regulation. Their cellular regulatory impact is determined not solely by their sheer number, which likely amounts to >2000 individual miRNAs in human, than by the regulatory effectiveness of single miRNAs. Although, one begins to develop an understanding of the complex mechanisms underlying miRNA–target interactions (MTIs), the overall knowledge of MTI functionality is still rather patchy. In this critical review, we summarize key features of mammalian MTIs. We especially highlight latest insights on (i) the dynamic make-up of miRNA binding sites including non-canonical binding sites, (ii) the cooperativity between miRNA binding sites, (iii) the adaptivity of MTIs through sequence modifications, (iv) the bearing of intra-cellular miRNA localization changes and (v) the role of cell type and cell status specific miRNA interaction partners. The MTI biology is discussed against the background of state-of-the-art approaches with particular emphasis on experimental strategies for evaluating miRNA functionality.

Graphical abstract



Introduction

Since their discovery in 1993 (1), microRNAs (miRNAs, miRs) have emerged as potent modulators of cellular gene expression. They are involved in the post-transcriptional regulation of almost all cellular processes and play consequently important roles in the development of many diseases. Accordingly, miRNAs have attracted great interest as potential novel tools for diagnosis and even therapy (2,3). The highly complex nature of the regulatory networks centered around miRNAs has, however, dampened the hopes initially associated with a rapid use of miRNAs in a clinical context. While one

is only slowly beginning to acknowledge the complexity of miRNA networks, many supposedly reliable findings must be regarded as preliminary. In addition, it is certainly not least due to the rapid development of miRNA research that many central terms, like the one of a miRNA ‘target’, are far from being uniformly and clearly defined. The lack of generally accepted definition renders statements blurred that operate with such terms. For example, many studies with rather heterogeneous definitions of miRNA targets refer to the statement that 60 % of all protein coding genes are potential targets (4). Such ambiguities have serious consequences if falsely defined

Received: August 2, 2023. Revised: October 23, 2023. Editorial Decision: November 10, 2023. Accepted: November 20, 2023

© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

targets are used in the context of miRNA–target networks. These networks have already an inherent fuzziness about them since they are by no means static structures but are subject to constant dynamic changes, not at least in response to varying cellular conditions (5–7). It is of utmost importance to achieve a greater clarity about the terminology including the definitions of miRNA targets and miRNA–target interactions.

Here, we provide a broad and systematic overview on the complex miRNA–target interactions (MTIs) with a special consideration of state-of-the-art approaches to experimentally assess MTIs. To this end we emphasize the factors that contribute most to the great variability of miRNA-to-target binding, the impact of the miRNA localization on their functionality and the mutual stoichiometric effects between miRNA and mRNA targets. Finally, we shed light on databases and their capacity to further our understanding of MTIs.

MiRNA biogenesis and database entries of miRNAs and their targets

Endogenous miRNAs arise during a complex biogenesis process, of which the main features are summarized in Figure 1. In brief, a hairpin-formed transcript is generated from endogenous DNA loci and stepwise processed into a 19–22 nucleotide (nt) miRNA duplex structure (8,9). Within the cytosol, this mature miRNA interacts with proteins of the Argonaute (Ago) family and is subsequently incorporated into the RNA induced silencing complex (RISC) (10). Canonical miRNA–target interactions are mediated by the ‘seed region’ that covers the nucleotides 2–8 at the miRNA’s 5′-end (11). Reverse-complementary miRNA binding sites, which are also referred to as miRNA responsive elements (MREs), are commonly located within the 3′ Untranslated Regions (3′UTRs) of the targeted messenger RNAs (mRNAs) (11,12), but can also map within 5′UTRs or the protein coding sequence (13,14). The binding ultimately results in a decrease of the corresponding protein levels, due to for example a RISC catalyzed decapping or deadenylation, degradation or inhibition of protein translation (15–17). The miRNA-coupled RISC (miRISC) can interfere with the translation machinery at various stages of the translation process, including initiation, post-initiation and elongation (18). Under specific conditions, as for example during cell cycle arrest, some miRNAs can also promote protein translation (19). This unusual miRNA functionality has first been reported in 2007 but there is a lack of further studies to substantiate this finding (20).

In the early times of miRNA research, single miRNAs were identified by classical Sanger sequencing and their cellular expression status was often experimentally verified (21). But high-throughput technologies have led to a tremendous increase in the amount of miRNA sequence data (22). Sequencing-based miRNA identification resulted in the annotation of numerous miRNAs, which found their way into various databases, such as miRBase (21–23). However, as of today only ~5 % of the human miRNA entries appear to be experimentally verified by other techniques such as northern blotting (23). Systematic evaluations indicate that many of the annotated sequences likely do not represent true miRNAs, but rather other RNA species or even sequencing artifacts (21,23,24). A premature and wrong annotation as true miRNAs has consequences not only for the understanding of biological networks, whose structure may be judged completely incorrect by considering false miRNAs, but also for clinical

settings in which miRNAs and/or their targets are envisaged as starting points for therapeutic interventions (2,25). This caveat is acknowledged in recent miRBase releases by a rating of confidence for miRNA candidates. The rating relies on specific criteria like the presence of characteristic 3′ overhangs as part of the mature miRNA duplex (22). Here, again the dimension of the problems becomes evident. Only ~35% of the human miRNA entries in the miRBase (v22.1) are classified as ‘high confidence’ miRNAs. Therefore, other databases were developed to complement and extend the miRBase (26). The miRCarta repository aims to provide a sensitive collection of every transcribed non-coding small RNA with properties similar to miRNAs, with the rationale to prevent that studies repeatedly claim novel miRNA candidates that have in fact been already reported by others (27). The MirGeneDB has emerged as the best resource for high fidelity resource for metazoan miRNAs. It excels by considering evolutionary aspects on miRNAs and in that all entries are manually curated by consequently applying established hallmarks of miRNA processing (28). In that, MirGeneDB has emerged as a second reference repository for miRNAs in addition to the miRBase.

The complex situation of miRNA identification is reflected in a relative broad range of estimates on the total number of miRNAs. Depending on the selected source of primary data e.g. MirGeneDB (v2.1) or miRBase (v22.1) the listed number of mature human miRNAs varies between 630 and 2 656 (22,28). *In vitro* studies indicate 750–900 human pri-miRNAs as potential DROSHA substrates (29,30). The true number of mature human miRNAs that are experimentally verified seems to be in between these counts and amount to slightly over 2 000 of which not all are annotated in miRbase yet (23). Overall, database entries of miRNAs should be viewed with some caution or better yet skepticism, as long as there is no thorough and robust characterization of a deposited miRNA. As a final remark, even constantly curated and updated databases do not prevent, that formerly annotated miRNAs, which have been removed from databases, are still investigated in recent publications as for example miR-1273g, which despite being withdrawn from the miRBase in version 22 (22) is still analyzed as a functional miRNA in seven publications since 2020. Removal from the database does, however, not necessarily imply the absence of functionality of such miRNAs, especially not the absence of non-canonical functions.

As for databases that list experimentally supported miRNA targets, the DIANA-TarBase allows retrieval of positive and negative miRNA targets per species, methodology, cell type and tissue (31). Verified MTIs from curated articles and CLIP-seq data are collected in the miRTarBase. It includes information on single-nucleotide polymorphisms, disease-related variants related to the binding efficiency of miRNA to their targets and extracellular miRNA expression profiles (32). Despite their usefulness, database entries of miRNAs and the targeted mRNAs should be viewed with some caution or better yet skepticism, as long as there is no thorough and robust characterization of the deposited miRNAs and miRNA targets.

MiRNA–target binding

Seed length, 3′ extended binding, and seedless binding

The efficiency of miRNA–target interactions (MTIs) depends on various factors as detailed in the following and summarized in Figure 2A. The RISC-coupled miRNA interacts with its specific mRNA target by Watson–Crick base-pairing. As




Figure 1. Scheme of the canonical miRNA biogenesis pathway. The first step of the canonical mammalian miRNA biogenesis encompasses the transcription of a primary miRNA (pri-miRNA) from endogenous DNA loci by RNA polymerase II. The primary transcript includes an imperfect hairpin structure that is cleaved by the DROSHA-DGCR8 complex into a 60–90 nt long precursor miRNA (pre-miRNA) with a two nucleotide (nt) 3' overhang. The pre-miRNA is transported from the nucleus to cytoplasm through the export protein XPO5 in a RAN-GTP dependent manner. The cytoplasmic miRNA becomes a substrate for the RNase DICER that forms a complex with the double-stranded RNA-binding protein TRBP. Following removal of the loop structure, a miRNA duplex of 19–22 nt in length interacts with proteins of the Argonaute (Ago) family. One strand is incorporated into the RNA induced silencing complex (RISC). The strand with a higher content of purines and a lower thermodynamic stability of the 5' end takes the dominant biological functionality i.e. it acts as functional miRNA that confers post-transcriptional regulation through RISC catalyzed mRNA degradation, mRNA destabilization or translation repression. [The functional portion of the miRNAs are indicated in red, the mRNA target is shown as a solid blue line, and the degraded mRNA as a dashed blue line. Interactions between miRNA and mRNA are indicated by opposite comb-shaped lines. The Droscha–DGCR8 complex is depicted by pink bodies, the export protein XPO5 by a violet cylinder, the DICER-TRBP complex by blue bodies, the RISC by a turquoise body and ribosomes by green bodies.]

abovementioned canonical target binding occurs at the seed region i.e. the nucleotides 2–8 of the miRNA's 5' end. As a rule of thumb, there is a hierarchy in the regulatory efficiency depending on the number of seed nucleotides involved in the target interaction (8mer > 7-mer-m8 > 7-mer-A1 > 6-mer) (33,34). However, even 5-mer MTIs could play essential roles for the miRNA targeting as recently shown for miR-34a-5p in human cells (35). Beyond the seed region, additional binding of the miRNA's 3' sequence, in the following referred to as 3' extended binding, can also affect the target regulation. Various studies have shown that human miRNAs of the same

family e.g. the let-7 family, can regulate different sets of targets, even though these miRNAs share the same seed region and similar 5' sequences (5,14). It has been shown as early as in 2007 that extended base pairing within the 3' region of a miRNA can enhance its regulatory efficiency on certain targets. This binding is commonly denoted as 'supplementary binding' (36). In addition, 3' extended binding can also compensate for mismatches within the miRNA seed region. The latter one is denoted as 'compensatory binding' (4). While former analyses assumed a principal involvement of the miRNA 3' nucleotides 13–16 (36), recent data provide evidence that




Figure 2. Overview on miRNA–target bindings and miRNA localization changes. **(A)** The regulatory capacity of MTIs is a function of the length of binding interaction between the miRNA seed sequence and the mRNA target, the presence of 3′ binding sites, the cooperation between multiple miRNA-responsive elements and the modification of both, the miRNAs and target sequences through e.g. A-to-I RNA editing or 3′UTR shortening. **(B)** Intra-cellular miRNA sub-localizations include membranous compartments like the nucleus or mitochondria and non-membranous compartments like granules. Extracellular miRNA localization can result from secretion of vesicles like exosomes. [MiRNAs are indicated as red lines, mRNAs as blue lines, interactions between miRNA and mRNA by opposite comb-shaped lines. Length variations are depicted by dashed two-sided arrows and translocations by solid two-sided arrows. Ribosomes are shown as green bodies, RISC as turquoise bodies. Sequence shortening is symbolized by cutting scissors and sequence exchanges by dotted rectangles.]

3′ extended binding can encompass the entire 3′ miRNA sequence (37). The manifestation of 3′ extended binding modes appears to depend on various factors, such as the distribution of G residues within the miRNA sequence (37).

In rare cases, MTIs have been described to even take place without the involvement of the seed region (38). This ‘seedless’ pairing mode is likely prompted by a weak pairing stability of the seed region, due to an AU-rich sequence composition (39) and can be supported by an interplay with nearby canonical miRNA binding sites as shown by analyses in *Caenorhabditis elegans* (*C. elegans*) (40). It remains to be seen if these results are generalizable and if they are applicable to human cells.

Repetitive binding and associated binding sites

There is accumulating evidence that the number and distribution of miRNA binding sites within the 3′UTR likely impacts the regulation of specific targets (41). Repetitive binding sites for the same miRNA and adjacent binding sites for different miRNAs can both result in a higher regulatory efficiency (42,43). In general, a distinction must be made between functional cooperativity and binding cooperativity. While functional cooperativity describes the summation of miRNA-related effects, binding cooperativity is characterized by the physical interaction of multiple RISCs, which support each other in their binding to the respective mRNA target (43). In the broadest sense, functional cooperativity can not only be the targeting of multiple miRNA responsive elements within the same mRNA but also of different mRNAs within the same functional pathway (43,44). In the latter case, the summative effects lead to efficient regulation of the affected pathway. As for the binding cooperativity, it has long been assumed that it requires a close localization of the interacting binding sites at distances between 8–39 nt (36,45). These distance restrictions

that rely on a linear perspective have been challenged by recent studies that suggest a further impact of the target secondary structure (46). Overall, the interactivity of binding sites renders the analysis of MTIs rather complicated, since the effect of a single miRNAs can only be adequately described in the context with co-expressed miRNAs, with each of the resulting MTIs depending on factors like the accessible seed sequence and the target structure.

Editing within and outside of the miRNA seed region

Adding a further level of complexity, miRNAs as well as mRNA target sequences are not static but are subject to changes. Sequence changes through RNA editing can e.g. be introduced into the miRNA seed region thereby altering its binding capacity to target mRNAs (47). Likewise, RNA editing events that occur outside the seed region can impact the processing and the loading efficiency of miRNAs into the RISC, thereby contributing to a flexible responsiveness to different cellular conditions (48). Editing events have been identified at various stages of the miRNA maturation process (48,49) and miRNA editing has been described for many different human tissues, particularly for neuronal cells (49). Corresponding sequence changes are attributed to ADARs (adenosine deaminases acting on RNAs) causing exchanges of adenosine (A) to inosine (I). Additionally, cytidine deaminase enzymes (AID/APOBECs family) have been described to cause cytidine (C) to uridine (U) editing. Particularly, the A-to-I miRNA editing has frequently been shown to alter the targeting of oncogenes in context with cancers (50). There is recent evidence for a preferential editing of distinct miRNA subpopulations that share specific precursor secondary structures i.e. efficient double-strand pairing at the farthest opposite end (‘root region’) of the hairpin-loop (47). In contrast,

the C-to-U miRNA editing is much less studied and apparently occurs only under specific physiological conditions such as cellular hypoxia (51). Although not the immediate focus of this review, the role of different miRNA isoforms (isomiRs) that becomes increasingly more recognized (52–55) needs to be acknowledged to ultimately understand the relationship between altered miRNA levels and their regulatory effects.

Editing and length variations of target 3'UTRs

Besides its bearing for microRNA sequences, RNA editing events can also affect the 3'UTR sequence of the mRNA targets to vary e.g. the accessibility of certain binding sites (56). As a further factor, the length of the 3'UTRs can also be subject to changes (57). As recently shown, the prevalence of long 3'UTR variants with multiple miRNA binding sites likely affects the miRNA mediated target regulation in mammalian axon growth (41). The 3'UTR length variations can also affect the formation of RNA secondary and tertiary structures, which in turn can change the accessibility of the miRNA binding sites (58,59). Extensive 3'UTR shortening as the result of alternative transcript processing has for example been described to cause a peripheral positioning of miRNA binding sites, thereby enhancing the miRNA binding capacity during the proliferation of human embryonic fibroblasts (7).

Functional effects of different miRNA localization

Besides their known cytoplasmic functions in the translation process, miRNAs can also exert other specific regulatory tasks depending on their subcellular localization (Figure 2B). The intra-cellular localizations include membranous organelles like the nucleus or the mitochondria and non-membranous compartments as for example ribonucleoprotein granules (60).

There is accumulating evidence that miRNAs, which are localized within the nucleus are involved in the regulation of the transcription process (61–64). To exert miRNA guided transcriptional regulations, the mature miRNA-coupled RISC is transported from the cytoplasm into the nucleus. Nuclear miRNA shuttling is likely mediated by specific transporter proteins including importin-8, importin- α/β and XPO1 (65–67). Since the amount of a translocated miRNA very likely impacts its regulatory function in the nucleus, it is expected to be controlled by a number of different factors including distinct sequence motifs (6,68,69). In addition, specific environmental conditions such as hypoxic stress have been associated with miRNA shuttling between the cytoplasm and the nucleus (6). Within the nucleus, the miRISC complexes can bind to promoter sequences and to DNA regulatory elements, thereby impacting the recruiting and binding of transcription factors and chromatin remodeling factors (70,71). The miRNA guided expressional regulations have been described to result either in transcriptional gene activation (TGA) or transcriptional gene silencing (TGS) (71). Examples include the transcriptional up-regulation of *STAT3* by miR-551b-3p (72) or the down-regulation of the transcription factor EB by miR-30b-5p (73).

As for their intracytoplasmic sub-localization, it has been hypothesized that miRNAs such as miR-762 can be transported into the mitochondria to silence mitochondria resident transcripts (74). A dysregulation of this miRNA has recently been associated with immunological changes in Parkinson's Disease and with myocardial infarction (74,75). There is, however, an ongoing debate on the mechanism of mito-

chondrial microRNA (mitomiR) translocation. Recent analyses indicate that shuttling into the mitochondria may be mediated by interactions of the miRNA coupled RISC with specific transport proteins such as the Polynucleotide Phosphorylase (PNPase) (76). As of now the circumstantial evidence for a presumed miRNA functionality in mitochondria awaits further experimental confirmation (77).

Among the miRNAs that co-locate with non-membranous granules, there are miRNAs that group together with processing bodies (P-bodies/PBs) (78). Recent analyses found both, active and inactive miRNAs enriched in PBs. While regulatory active miRNAs were found to only temporarily associate with the P-bodies, inactive miRNAs were found to be stably anchored, suggesting a mechanism, which sets unused miRNAs apart (79).

In addition to their localization within cellular compartments, miRNAs are also found in vesicular structures like exosomes. It is generally assumed that these miRNAs can be transferred between distant cells and likely act as part of the inter-cellular communication (80). However, the specific steps of the corresponding transport processes are only partially understood. Most recent findings suggest that vesicular miRNA export is mediated by specific RNA-binding proteins like Alyref and Fus (81). A selective sorting of mRNAs into exosomes appears to be directed by cell type specific consensus sequences of 4–7 nt (EXOmotifs), while an intracellular retention of miRNAs is mediated by different motifs (CELLmotifs) (81).

Mutual stoichiometric effects between miRNAs and target genes

Stoichiometric effects of miRNA on mRNA targets

The miRNA function is further modulated by interactions between different miRNAs, mRNA targets, other types of non-coding RNAs and RNA binding proteins (Figure 3). The stoichiometric ratios of these interacting partners play a critical role for the regulatory effects of miRNAs. Various studies have shown that altered miRNA expression levels impact the miRNA targeting suggesting a concentration dependence of miRNA regulatory effects (5,82). A meaningful cellular miRNA effect is assumed to require a minimal cellular miRNA abundance (5,83). For miRNAs that are present in sufficient quantities their biological effect is likely determined by a competition for limited cellular resources, most notably the available RISCs (84,85). Quantitative studies describe cellular miRNAs levels in the range of $10\text{--}10^5$ miRNA molecules per cell (86), with only a small fraction of highly abundant miRNAs (86,87). The small fraction of these highly abundant miRNAs most likely exert dominant regulatory effects in these competitions (83). However, the role of the numerous non-highly abundant miRNAs should not be underestimated. These miRNAs have also the potential to exert important regulatory functions, for example through a high binding affinity to cellular key targets like transcription factors (88,89). In addition, non-highly abundant miRNAs may potentiate their regulatory effectiveness not only by functional cooperation, but also by multiple rounds of target regulation (90–93).

The miRNA functionality is furthermore influenced by the four Ago protein paralogs (Ago1-4) that are expressed in mammalian somatic cells. Although, there are some redundancies between the miRNA related function of these paralogs (94), there are specific functional differences including their ability to efficiently cleave a targeted mRNA (95).




Figure 3. Scheme representation on the diversity of miRNA interactomes. **(A)** Different miRNAs compete for cellular resources, including the available RISCs. There are specific preferences of the miRNAs for their interaction with different Ago paralogs as central part of the RISC. **(B)** Target mRNAs and competing endogenous RNA species, like circular RNAs (circRNAs), contest for miRNA binding. **(C)** Different mRNAs compete for RISC bound miRNAs. **(D)** RNA-binding proteins (RBPs) modulate accessibility of a mRNA target site for miRNAs. [Different miRNAs are depicted in red, pink and orange, respectively. Different mRNAs (targets) are shown in shades of blue and ceRNAs in violet. A different molecular abundance is indicated by a different number of miRNAs or mRNAs, respectively. RISCs are shown by turquoise and RNA binding proteins by greyish bodies. Functional interactions are indicated by arrows and sequence interactions by opposite comb-shaped lines.]

Different tissues and cell types show variable expression levels of the different Agos (96), possibly contributing to context specific miRNA functions. Individual miRNAs and even different isomiRs have been found to preferentially interact with specific Ago paralogs (97–99). Furthermore, the expression of specific Ago subtypes can be impacted by the prevalence and abundance of certain microRNAs, suggesting a feed-back mechanism (100).

Stoichiometric effects of mRNA targets on miRNAs

The miRNA expression not only impacts the target expression but vice versa the amount of mRNA target impacts the miRNA abundance by affecting the turnover rate of a miRNA. Analyses of mammalian cells provide evidence that 3' extended and seedless binding modes can trigger decay of miRNAs through a process termed 'target-directed miRNA degradation' (TDMD) (101,102). Current findings also show that the prevalence of certain mRNA targets and a high target-to-miRNA ratio likely promote TDMD, indicating a multifactorial and context dependent coordination of the process (103,104). As for the underlying mechanism, it is assumed that the Ago changes its conformation during the target interaction, so that the miRNA's 3' end is exposed and becomes accessible for 3'-tail trimming and exonuclease-based degradation (105). Another quantitative aspect is, that a high target-

to-miRNA ratio increases the likelihood for specific miRNA target interactions at the expense of other target bindings (88,89). This target competition is ultimately the result of a molecular titration process (89,106).

Impact of miRNA sponges and RNA-binding proteins

A final but relevant quantitative aspect of MTIs concerns the embedding of miRNA–target networks in larger networks of various competing endogenous RNAs (ceRNAs), also referred to as endogenous miRNA sponges. Due to competing binding sites, these ceRNAs likely keep miRNAs from binding to their mRNA targets (107,108). The ceRNAs include various types of non-coding RNAs, such as long non-coding RNAs (lncRNAs) or circular RNAs (circRNAs) (107,109–111). Mathematical modeling predicts favorable settings for miRNA–ceRNA interactions under the condition that nearly equimolar expression rates are given (108,112). Beyond the interactions of miRNAs with their mRNA targets and other types of RNAs, there is accumulating evidence, that the prevalence of RNA-binding proteins (RBPs) can also impact miRNA-mediated target regulations (113). Although most RBPs likely modulate local 3'UTR secondary structures of mRNA targets to enhance miRNA binding capability (114), there are also reports about antagonistic effects of RBPs, including Human antigen R (HuR), through the blocking of miRNA binding

sites (115,116). Additionally, miRNA expression levels can be controlled by direct and indirect effects of RBPs, including AUF1 (AU-binding factor 1), DDX17 (DEAD-box helicase 17) and ILF3 (interleukin enhancer binding factor 3) (117–120).

Experimental access to MTIs

MiRNA regulations usually result in rather moderate effects on the expression levels of single targets (121). The limitations are compensated in cases where the target proteins of these miRNAs map within the same regulatory pathway (122–124). However, the detection of the effects of a given miRNA on single target mRNAs remains rather challenging. To this end common criteria and tools have been developed for the *in silico* prediction of potential miRNA targets. These *in silico* tools have thoroughly been reviewed elsewhere (125). Functional enrichment analysis by other computational tools like ‘GeneTrail’ (126), can further enhance the validation rates of experimental testing strategies (122,127). In the following, we focus on the experimental validation of MTIs.

Induced altered miRNA expression

In recent years, a variety of different strategies have been developed to allow for efficient miRNA manipulations. Common strategies to induce miRNA overexpression include the use of expression plasmids or synthetic miRNAs (miRNA mimics) (2). However, miRNA overexpression approaches usually lead to unphysiologically high expression levels and to off-target effects, in part due to the utilization of cellular resources like RISCs, which will be less or no longer available for endogenous miRNAs (128).

Common strategies for miRNA inhibition include assays to either down-regulate or functionally obstruct endogenous miRNAs. As most recently shown, miRNA down-regulation can for example be achieved by sequence specific degradations using miRNases conjugated to miRNA-binding antisense oligonucleotides (129). Alternatively, a functional inhibition of miRNAs can be achieved by complementary ‘RNA zippers’ that allow for a sequence specific end-to-end connection of endogenous miRNA molecules (130). To abolish miRNA expression, miRNA knockouts have been achieved by genome editing techniques including TALEN (Transcription Activator-like Effector Nuclease) or CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9) (131–133). As for the miRNA overexpression, off-target effects have been reported for both miRNA inhibition and miRNA knockouts (128,134). This issue has recently been addressed by sequence specific nucleic acid masks and peptide nucleic acids (PNAs) that were designed to block binding sites on mRNA targets without affecting the miRNAs themselves. These approaches have been shown to effectively inhibit miRNA functions in MTI studies (135,136).

An issue that is highly relevant for both, induced miRNA overexpression and inhibition, concerns the distance between the time-point of manipulation and the time-point of measurement. The detection of related downstream effects is affected by cellular turnover rates. In detail, the amounts of transiently transfected oligonucleotides for miRNA manipulations are subject to cellular turnover (137–139). The same applies to miRNA targets, which can be measured as mRNAs or proteins, each with their specific cellular half-lives (140,141). Al-

though, there are attempts to provide guidelines for the estimation of optimal time-points for miRNA downstream analysis (142), this will remain a task that has to be optimized, anew in each experiment.

MiRNA and target expression analyses

Various experimental strategies have been employed to examine different aspects of the miRNA regulatory process (Figure 4). First information on the miRNA-mRNA target interplay can be gained by approaches that integrate cellular expression data of miRNAs and their predicted targets (131,143,144). Conclusive experimental data are obtained from comparisons between healthy and diseased cells or as the result of an experimentally altered miRNA expression. Expression analysis on the RNA level is carried out by either low-throughput methods like quantitative PCR (qPCR) or high-throughput RNA detection methods like RNA-sequencing (145) that have largely replaced formerly employed array-based techniques. Target analysis on the mRNA level is frequently complemented or even replaced by protein analyses, although most of the miRNA regulations appear to show their primary effects on the mRNA level (17,146). Depending on the task, proteins are analyzed by either low-throughput methods like Western blotting or immunostaining (147,148) or high-throughput methods like mass spectrometry (149,150).

A major advantage of these descriptive miRNA–target analyses is their independence of specific experimental settings, such as a model cell line. However, the detection of inverse correlation may be simply due to chance, especially when complex miRNA–target data sets are analyzed using a limited number of samples. Unfortunately, there are numerous manuscripts that fall in this category of randomness by reporting inverse miRNA–target correlations in a far too small number of samples. A further limitation of the observative approaches is that their data mostly result from the analysis of a single point in time. As addressed above, this caveat is for example relevant for processes in which target effects of a miRNA are found only with an extended time delay. Here, target effects can be readily overlooked in scenarios where a decay of the miRNA had occurred at the time when its biological effect becomes measurable by an altered target abundance. Likewise, miRNA regulatory effects may only be observable at specific cellular stages or at specific time-points of a disease process. Recent analyses address this challenge by evaluating time-series expression data during biological processes like for example T-cell activation (151). Other approaches attempt to associate miRNA and target expression levels by correlating datasets, even if they stem from different tissues (152,153). These analyses allow to identify common miRNA regulations but fall short in identifying cell type specific miRNA functions.

Reporter assays and immunoprecipitation-based approaches

A still limited in number of experimental approaches allow to validate for the miRNA-to-target binding. A common method of choice are reporter assays that use recombinant plasmids, which include a reporter gene (e.g. luciferase or GFP gene) under the post-transcriptional regulatory control of the potential target’s 3’ UTR sequence (154,155). The MTI is determined by measuring the reporter activity upon overexpression or inhibition of the respective miRNA (156). The experiment can be by sequence mutation of the potential miRNA binding site, either by a complete deletion or an exchange of the wildtype MRE, reverting the miRNA’s impact on the reporter (157). One has,




Figure 4. Experimental strategies for the identification of miRNA targets. MiRNA targets can be identified by comparisons of e.g. healthy vs. diseased cells or by downstream analysis upon experimental miRNA manipulations. Differential abundances of miRNAs and target mRNA are detectable by qPCR, microarray analyses, or next generation sequencing (NGS), differential levels of target proteins by western blot, immunostaining or mass spectrometry, direct interaction between miRNAs and their target mRNA by reporter assays or co-precipitation analyses, and down-stream miRNA effects by proliferation assays, viability assays or by assays tailored for specific miRNA regulated cell functions. [MiRNAs are indicated in red, target mRNAs in blue, and target proteins as blue spherical bodies. Interactions between miRNA and mRNA are depicted by opposite comb-shaped lines. Degradation of mRNA is indicated by dashed lines and reduction in protein expression by dashed outlines. Functional effects are symbolized by a grey shaded receptor icon. Ribosomes are shown as green bodies, RISCs as turquoise bodies.]

however, to bear in mind that alterations of the 3'UTR potentially create alternative binding sites and change the interactivity not only with the designated miRNA, but also with other endogenous miRNAs and RBPs (158,159). MiRNA seed mutations represent another option for the validation of reporter assays of MTIs. Here, one has to bear in mind that artificial sequence changes within the seed region potentially affect the half-life of miRNAs and may alter their targeting of endogenous mRNAs and the TDMD (160,161). In addition, there are attempts that use *in vivo* CRISPR screening for the identification of miRNAs targets by reverting the effects of mutated miRNA targets by mutated seed sequences (162).

A main advantage of the reporter assays is the possibility to measure the effects of miRNA–target binding in a functional setting. There are, however, several drawbacks in part due to necessary transfections, which lead to non-physiological miRNA and/or 3'UTR-target concentrations. To address this problem, chemically inducible expression constructs have recently been tested in context with reporter assays, mimicking

expression rates at physiological quantities (163). An additional drawback of the reporter assays is the common use of 3'UTR fragments instead of the full-length 3'UTRs. The potentially altered 3'UTR secondary structure of shorter fragments likely impacts the miRNA target binding. To address this caveat, efficient cloning protocols for the generation of full-length 3'UTR luciferase reporter constructs have recently been proposed (164,165). While a reporter-based analysis of 5'UTR reporter plasmids is also conceivable, it would be hard to implement the investigation of coding sequences. Furthermore, the assays are preferentially performed with cells that can readily be transfected with high efficiency like e.g. HeLa or HEK293 (Human Embryonic Kidney 293) cell lines (166,167). It is evident that their cellular context with the above-mentioned regulatory networks, including endogenous miRNA pools, ceRNAs and RBPs, is largely different from the cells of interest with the consequence that the miRNA target interaction detected in a reporter assay may not be found in other cell types. Finally, if done manually reporter

assays are rather time consuming in that they require several steps including cloning of the 3'UTR sequence and transfection of both the recombinant and appropriate control constructs, i.e. empty reporter vectors and miRNA negative controls. Recently developed high-throughput miRNA interaction reporter (*HiTmIR*) assays can help to render these assays more efficiently (122,127).

In addition to reporter assays, MTIs are frequently analyzed by approaches that use Ago immunoprecipitation followed by an examination of the bound miRNA and mRNA fractions (157). There are various modifications of these approaches like 'High-Throughput sequencing of RNA isolated by crosslinking immunoprecipitation' (HITS-CLIP), 'Cross-Linking Ligation and Sequencing of Hybrids' (CLASH) and 'Argonaute-RNA Immunoprecipitation' (AGO-RIP). In HITS-CLIP assays, UV-irradiation induces crosslinking of cellular Ago proteins together with the incorporated miRNAs and the bound target mRNA fractions. After immunoprecipitation with Ago-specific antibodies, complexed RNA fractions are purified and subjected to sequencing analysis (168). In the CLASH assays, base paired miRNAs and mRNA target fractions are linked by a ligation step to form a hairpin-like structure. In this way, CLASH allows the mapping of specific miRNAs-target pairs with high precision (169,170). In the AGO-RIP assays, a native pulldown of Ago-RNA-complexes overcomes common inefficiency of cross-linking procedures (171,172). The newest precipitation-based technique includes the use of biotinylated miRNAs, a formalin cross-linking step and a streptavidin-based pull-down of miRNA-DNA-complexes for the detection of nuclear miRNA functions (173). A major advantage of the precipitation-based approaches is that many different cell types can be examined and not just very specific cell models, as is the case with reporter assays. This, however, not necessarily implies the absence of major limitations. Precipitation-based approaches usually require large amounts of the considered miRNA. High endogenous expression levels are commonly achieved by induced expression (172). Additionally, precipitation-based approaches are often done with highly reproductive cell lines to compensate for the overall material loss during multiple experimental steps (174,175). This of course entails all drawbacks associated with cultured cell lines (176) and renders conclusion on true *in vivo* binding effects of miRNA problematic. A rather elaborate methodology has recently been published describing an efficiency enhanced pulldown of Ago2 proteins using transgenic introduced HaloTags (177). Although this method allows the use of primary tissue material from transgenic animals, cell samples may still need to be pooled from different individuals to provide sufficient material for the subsequent sequencing analysis (177). This bears the risk of high cellular heterogeneity within the resulting bulk data. Another disadvantage is that precipitation-based techniques only detect miRNA-target binding without providing evidence for the functional relevance of such binding. Without this evidence, a detected binding may have also occurred by chance. This could explain why recently published CLIP data only poorly correlated with target repression data in human cell lines (178). Recent studies complemented Ago immunoprecipitation by reporter assays or by miRNA titration tests, thereby adding functional validation of the detected binding sites (179,180).

As addressed above, the measurement of expression levels of target mRNAs or proteins offers a straightforward readout

for miRNA manipulations (147,148). This readout is, however, far from proving a link between a given miRNA and a biological effect. To robustly confirm such link in specific cellular contexts, appropriate assays are required. Although many targets like transcription factors offer themselves for specific downstream testing, frequent functional analyses in MTI studies address rather basic cellular functions e.g. by employing proliferation or viability assays without establishing a direct link to the actual miRNA target.

Conclusion

Since the discovery of miRNAs, significant insights into the complexity of MTIs have been gained. There is an increasing understanding of the dynamics of miRNA regulations, which acknowledges the variability of miRNA binding constellations, the context dependent modulation of miRNA sequences, the alteration of miRNA subcellular localizations and the impact of various endogenous interaction partners. There is also an increasing awareness of the context dependency of MTIs. The continuous improvement of experimental strategies increasingly considers the cellular context of miRNA regulations thereby contributing to more reliable definitions of miRNAs and miRNA targets and in consequence to a holistic view of their roles in cellular regulatory networks.

Data availability

No new data were generated or analysed in support of this research.

Acknowledgements

Author contributions: Caroline Diener, Saarland University (USAAR), Institute of Human Genetics, 66421 Homburg, Germany; Andreas Keller, Saarland University (USAAR), Chair for Clinical Bioinformatics, Saarland Informatics Campus, 66123 Saarbrücken, Germany and Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz-Centre for Infection Research (HZI), 66123 Saarbrücken, Germany; Eckart Meese, Saarland University (USAAR), Institute of Human Genetics, 66421 Homburg, Germany

Funding

This study was supported by the Hans-und-Ruth-Giessen-Stiftung (2021) and the Hedwig-Stalter-Stiftung (2022) to Diener C.

Conflict of interest statement

A.K. was scientific advisor of Firalis, a company developing among others miRNA biomarkers for neurological disorders.

This paper is linked to: [doi:10.1093/nar/gkad1155](https://doi.org/10.1093/nar/gkad1155), [doi:10.1093/nar/gkad1235](https://doi.org/10.1093/nar/gkad1235), [doi:10.1093/nar/gkae003](https://doi.org/10.1093/nar/gkae003), [doi:10.1093/nar/gkae017](https://doi.org/10.1093/nar/gkae017).

References

1. Lee, R.C., Feinbaum, R.L. and Ambros, V. (1993) The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell*, 75, 843–854.

2. Diener, C., Keller, A. and Meese, E. (2022) Emerging concepts of miRNA therapeutics: from cells to clinic. *Trends Genet.*, **38**, 613–626.
3. Fehlmann, T., Lehallier, B., Schaum, N., Hahn, O., Kahraman, M., Li, Y., Grammes, N., Geffers, L., Backes, C., Balling, R., *et al.* (2020) Common diseases alter the physiological age-related blood microRNA profile. *Nat. Commun.*, **11**, 5958.
4. Friedman, R.C., Farh, K.K., Burge, C.B. and Bartel, D.P. (2009) Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.*, **19**, 92–105.
5. Brancati, G. and Grosshans, H. (2018) An interplay of miRNA abundance and target site architecture determines miRNA activity and specificity. *Nucleic Acids Res.*, **46**, 3259–3269.
6. Turunen, T.A., Roberts, T.C., Laitinen, P., Vaananen, M.A., Korhonen, P., Malm, T., Yla-Herttuala, S. and Turunen, M.P. (2019) Changes in nuclear and cytoplasmic microRNA distribution in response to hypoxic stress. *Sci. Rep.*, **9**, 10332.
7. Hoffman, Y., Bublik, D.R., Ugalde, A.P., Elkon, R., Biniashvili, T., Agami, R., Oren, M. and Pilpel, Y. (2016) 3'UTR shortening potentiates MicroRNA-based repression of pro-differentiation genes in proliferating human cells. *PLoS Genet.*, **12**, e1005879.
8. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*, **116**, 281–297.
9. Leitao, A.L. and Enguita, F.J. (2022) A structural view of miRNA biogenesis and function. *Noncoding RNA*, **8**, 10.
10. Gregory, R.I., Chendrimada, T.P., Cooch, N. and Shiekhattar, R. (2005) Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. *Cell*, **123**, 631–640.
11. Lewis, B.P., Burge, C.B. and Bartel, D.P. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell*, **120**, 15–20.
12. Gu, S., Jin, L., Zhang, F., Sarnow, P. and Kay, M.A. (2009) Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. *Nat. Struct. Mol. Biol.*, **16**, 144–150.
13. Lytle, J.R., Yario, T.A. and Steitz, J.A. (2007) Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. *Proc. Natl. Acad. Sci. U.S.A.*, **104**, 9667–9672.
14. Broughton, J.P., Lovci, M.T., Huang, J.L., Yeo, G.W. and Pasquinelli, A.E. (2016) Pairing beyond the seed supports MicroRNA targeting specificity. *Mol. Cell*, **64**, 320–333.
15. Wu, L., Fan, J. and Belasco, J.G. (2006) MicroRNAs direct rapid deadenylation of mRNA. *Proc. Natl. Acad. Sci. U.S.A.*, **103**, 4034–4039.
16. Behm-Ansmant, I., Rehwinkel, J., Doerks, T., Stark, A., Bork, P. and Izaurralde, E. (2006) mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. *Genes Dev.*, **20**, 1885–1898.
17. Eichhorn, S.W., Guo, H., McGeary, S.E., Rodriguez-Mias, R.A., Shin, C., Baek, D., Hsu, S.H., Ghoshal, K., Villen, J. and Bartel, D.P. (2014) mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues. *Mol. Cell*, **56**, 104–115.
18. Oliveto, S., Mancino, M., Manfrini, N. and Biffo, S. (2017) Role of microRNAs in translation regulation and cancer. *World J. Biol. Chem.*, **8**, 45–56.
19. Vasudevan, S., Tong, Y. and Steitz, J.A. (2007) Switching from repression to activation: microRNAs can up-regulate translation. *Science*, **318**, 1931–1934.
20. Ni, W.J. and Leng, X.M. (2016) miRNA-dependent activation of mRNA translation. *Microna*, **5**, 83–86.
21. Ludwig, N., Becker, M., Schumann, T., Speer, T., Fehlmann, T., Keller, A. and Meese, E. (2017) Bias in recent miRBase annotations potentially associated with RNA quality issues. *Sci. Rep.*, **7**, 5162.
22. Kozomara, A., Birgaoanu, M. and Griffiths-Jones, S. (2019) miRBase: from microRNA sequences to function. *Nucleic Acids Res.*, **47**, D155–D162.
23. Alles, J., Fehlmann, T., Fischer, U., Backes, C., Galata, V., Minet, M., Hart, M., Abu-Halima, M., Grasser, F.A., Lenhof, H.P., *et al.* (2019) An estimate of the total number of true human miRNAs. *Nucleic Acids Res.*, **47**, 3353–3364.
24. Fromm, B., Billipp, T., Peck, L.E., Johansen, M., Tarver, J.E., King, B.L., Newcomb, J.M., Sempere, L.F., Flatmark, K., Hovig, E., *et al.* (2015) A uniform system for the annotation of vertebrate microRNA genes and the evolution of the human microRNAome. *Annu. Rev. Genet.*, **49**, 213–242.
25. Johnson, K.C., Johnson, S.T., Liu, J., Chu, Y. and Corey, D.R. (2022) Prioritizing annotated miRNAs: only a small percentage are candidates for biological regulation. bioRxiv doi: <https://doi.org/10.1101/2022.10.18.512653>, 18 October 2022, preprint: not peer reviewed.
26. Fromm, B., Keller, A., Yang, X., Friedlander, M.R., Peterson, K.J. and Griffiths-Jones, S. (2020) Quo vadis microRNAs? *Trends Genet.*, **36**, 461–463.
27. Backes, C., Fehlmann, T., Kern, F., Kehl, T., Lenhof, H.P., Meese, E. and Keller, A. (2018) miRCarta: a central repository for collecting miRNA candidates. *Nucleic Acids Res.*, **46**, D160–D167.
28. Fromm, B., Hoye, E., Domanska, D., Zhong, X., Aparicio-Puerta, E., Ovchinnikov, V., Umu, S.U., Chabot, P.J., Kang, W., Aslanzadeh, M., *et al.* (2022) MirGeneDB 2.1: toward a complete sampling of all major animal phyla. *Nucleic Acids Res.*, **50**, D204–D210.
29. Kim, K., Baek, S.C., Lee, Y.Y., Bastiaanssen, C., Kim, J., Kim, H. and Kim, V.N. (2021) A quantitative map of human primary microRNA processing sites. *Mol. Cell*, **81**, 3422–3439.
30. Rice, G.M., Shivashankar, V., Ma, E.J., Baryza, J.L. and Nuti, R. (2020) Functional atlas of primary miRNA maturation by the microprocessor. *Mol. Cell*, **80**, 892–902.
31. Vlachos, I.S., Paraskevopoulou, M.D., Karagkouni, D., Georgakilas, G., Vergoulis, T., Kanellos, I., Anastasopoulos, I.L., Manioulis, S., Karathanou, K., Kalfakakou, D., *et al.* (2015) DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. *Nucleic Acids Res.*, **43**, D153–D159.
32. Huang, H.Y., Lin, Y.C., Cui, S., Huang, Y., Tang, Y., Xu, J., Bao, J., Li, Y., Wen, J., Zuo, H., *et al.* (2022) miRTarBase update 2022: an informative resource for experimentally validated miRNA–target interactions. *Nucleic Acids Res.*, **50**, D222–D230.
33. McGeary, S.E., Lin, K.S., Shi, C.Y., Pham, T.M., Bisaria, N., Kelley, G.M. and Bartel, D.P. (2019) The biochemical basis of microRNA targeting efficacy. *Science*, **366**, eaav1741.
34. Bartel, D.P. (2009) MicroRNAs: target recognition and regulatory functions. *Cell*, **136**, 215–233.
35. Hart, M., Kern, F., Backes, C., Rheinheimer, S., Fehlmann, T., Keller, A. and Meese, E. (2018) The deterministic role of 5-mers in microRNA-gene targeting. *RNA Biol.*, **15**, 819–825.
36. Grimson, A., Farh, K.K., Johnston, W.K., Garrett-Engle, P., Lim, L.P. and Bartel, D.P. (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. *Mol. Cell*, **27**, 91–105.
37. McGeary, S.E., Bisaria, N., Pham, T.M., Wang, P.Y. and Bartel, D.P. (2022) MicroRNA 3'-compensatory pairing occurs through two binding modes, with affinity shaped by nucleotide identity and position. *eLife*, **11**, e69803.
38. Lal, A., Navarro, F., Maher, C.A., Maliszewski, L.E., Yan, N., O'Day, E., Chowdhury, D., Dykxhoorn, D.M., Tsai, P., Hofmann, O., *et al.* (2009) miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3'UTR microRNA recognition elements. *Mol. Cell*, **35**, 610–625.
39. Moore, M.J., Scheel, T.K., Luna, J.M., Park, C.Y., Fak, J.J., Nishiuchi, E., Rice, C.M. and Darnell, R.B. (2015) miRNA–target chimeras reveal miRNA 3'-end pairing as a major determinant of Argonaute target specificity. *Nat. Commun.*, **6**, 8864.
40. Flamand, M.N., Gan, H.H., Mayya, V.K., Gunsalus, K.C. and Duchaine, T.F. (2017) A non-canonical site reveals the cooperative mechanisms of microRNA-mediated silencing. *Nucleic Acids Res.*, **45**, 7212–7225.
41. Farberov, L., Ionescu, A., Zoabi, Y., Shapira, G., Ibraheem, A., Azan, Y., Perlson, E. and Shomron, N. (2023) Multiple copies of

- microRNA binding sites in long 3'UTR variants regulate axonal translation. *Cells*, **12**, 233.
42. Gebert, L.F.R. and MacRae, I.J. (2019) Regulation of microRNA function in animals. *Nat. Rev. Mol. Cell Biol.*, **20**, 21–37.
 43. Broderick, J.A., Salomon, W.E., Ryder, S.P., Aronin, N. and Zamore, P.D. (2011) Argonaute protein identity and pairing geometry determine cooperativity in mammalian RNA silencing. *RNA*, **17**, 1858–1869.
 44. Shu, J., Silva, B., Gao, T., Xu, Z. and Cui, J. (2017) Dynamic and modularized MicroRNA regulation and its implication in human cancers. *Sci. Rep.*, **7**, 13356.
 45. Saetrom, P., Heale, B.S., Snove, O. Jr, Aagaard, L., Alluin, J. and Rossi, J.J. (2007) Distance constraints between microRNA target sites dictate efficacy and cooperativity. *Nucleic Acids Res.*, **35**, 2333–2342.
 46. Diener, C., Hart, M., Fecher-Trost, C., Knittel, J., Rheinheimer, S., Meyer, M.R., Mayer, J., Flockerzi, V., Keller, A. and Meese, E. (2023) Outside the limit: questioning the distance restrictions for cooperative miRNA binding sites. *Cell. Mol. Biol. Lett.*, **28**, 8.
 47. Ishiguro, S., Galipon, J., Ishii, R., Suzuki, Y., Kondo, S., Okada-Hatakeyama, M., Tomita, M. and Ui-Tei, K. (2018) Base-pairing probability in the microRNA stem region affects the binding and editing specificity of human A-to-I editing enzymes ADAR1-p110 and ADAR2. *RNA Biol.*, **15**, 976–989.
 48. Correia de Sousa, M., Gjorgjieva, M., Dolicka, D., Sobolewski, C. and Foti, M. (2019) Deciphering miRNAs' action through miRNA editing. *Int. J. Mol. Sci.*, **20**, 6249.
 49. Li, L., Song, Y., Shi, X., Liu, J., Xiong, S., Chen, W., Fu, Q., Huang, Z., Gu, N. and Zhang, R. (2018) The landscape of miRNA editing in animals and its impact on miRNA biogenesis and targeting. *Genome Res.*, **28**, 132–143.
 50. Marceca, G.P., Tomasello, L., Distefano, R., Acunzo, M., Croce, C.M. and Nigita, G. (2021) Detecting and characterizing A-To-I microRNA editing in cancer. *Cancers (Basel)*, **13**, 1699.
 51. Sharma, S., Patnaik, S.K., Kemer, Z. and Baysal, B.E. (2017) Transient overexpression of exogenous APOBEC3A causes C-to-U RNA editing of thousands of genes. *RNA Biol.*, **14**, 603–610.
 52. Aparicio-Puerta, E., Hirsch, P., Schmartz, G.P., Fehlmann, T., Keller, V., Engel, A., Kern, F., Hackenberg, M. and Keller, A. (2023) isomiRdb: microRNA expression at isoform resolution. *Nucleic Acids Res.*, **51**, D179–D185.
 53. Wang, Y., Soneson, C., Malinowska, A.L., Laski, A., Ghosh, S., Kanitz, A., Gebert, L.F.R., Robinson, M.D. and Hall, J. (2021) MiR-CLIP reveals iso-miR selective regulation in the miR-124 targetome. *Nucleic Acids Res.*, **49**, 25–37.
 54. Kim, H., Kim, J., Kim, K., Chang, H., You, K. and Kim, V.N. (2019) Bias-minimized quantification of microRNA reveals widespread alternative processing and 3' end modification. *Nucleic Acids Res.*, **47**, 2630–2640.
 55. Yu, F., Pillman, K.A., Neilsen, C.T., Toubia, J., Lawrence, D.M., Tsykin, A., Gantier, M.P., Callen, D.F., Goodall, G.J. and Bracken, C.P. (2017) Naturally existing isoforms of miR-222 have distinct functions. *Nucleic Acids Res.*, **45**, 11371–11385.
 56. Brummer, A., Yang, Y., Chan, T.W. and Xiao, X. (2017) Structure-mediated modulation of mRNA abundance by A-to-I editing. *Nat. Commun.*, **8**, 1255.
 57. Navarro, E., Mallen, A. and Hueso, M. (2021) Dynamic variations of 3'UTR length reprogram the mRNA regulatory landscape. *Biomedicines*, **9**, 1560.
 58. Gan, H.H. and Gunsalus, K.C. (2019) The role of tertiary structure in MicroRNA target recognition. *Methods Mol. Biol.*, **1970**, 43–64.
 59. Rolle, K., Piwecka, M., Belter, A., Wawrzyniak, D., Jeleniewicz, J., Barciszewska, M.Z. and Barciszewski, J. (2016) The sequence and structure determine the function of mature human miRNAs. *PLoS One*, **11**, e0151246.
 60. Akgul, B. and Erdogan, I. (2018) Intracytoplasmic re-localization of miRISC Complexes. *Front. Genet.*, **9**, 403.
 61. Younger, S.T. and Corey, D.R. (2011) Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. *Nucleic Acids Res.*, **39**, 5682–5691.
 62. Johnson, K.C. and Corey, D.R. (2023) RNAi in cell nuclei: potential for a new layer of biological regulation and a new strategy for therapeutic discovery. *RNA*, **29**, 415–422.
 63. Kim, D.H., Saetrom, P., Snove, O. Jr and Rossi, J.J. (2008) MicroRNA-directed transcriptional gene silencing in mammalian cells. *Proc. Natl. Acad. Sci. U.S.A.*, **105**, 16230–16235.
 64. Huang, V., Zheng, J., Qi, Z., Wang, J., Place, R.F., Yu, J., Li, H. and Li, L.C. (2013) Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells. *PLoS Genet.*, **9**, e1003821.
 65. Wei, Y., Li, L., Wang, D., Zhang, C.Y. and Zen, K. (2014) Importin 8 regulates the transport of mature microRNAs into the cell nucleus. *J. Biol. Chem.*, **289**, 10270–10275.
 66. Chaston, J.J., Stewart, A.G. and Christie, M. (2017) Structural characterisation of TNRC6A nuclear localisation signal in complex with importin- α . *PLoS One*, **12**, e0183587.
 67. Castanotto, D., Lingeman, R., Riggs, A.D. and Rossi, J.J. (2009) CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs. *Proc. Natl. Acad. Sci. U.S.A.*, **106**, 21655–21659.
 68. Hwang, H.W., Wentzel, E.A. and Mendell, J.T. (2007) A hexanucleotide element directs microRNA nuclear import. *Science*, **315**, 97–100.
 69. Jeffries, C.D., Fried, H.M. and Perkins, D.O. (2011) Nuclear and cytoplasmic localization of neural stem cell microRNAs. *RNA*, **17**, 675–686.
 70. Sadakierska-Chudy, A. (2020) MicroRNAs: diverse mechanisms of action and their potential applications as cancer epi-therapeutics. *Biomolecules*, **10**, 1285.
 71. Liu, H., Lei, C., He, Q., Pan, Z., Xiao, D. and Tao, Y. (2018) Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer. *Mol. Cancer*, **17**, 64.
 72. Chaluvally-Raghavan, P., Jeong, K.J., Pradeep, S., Silva, A.M., Yu, S., Liu, W., Moss, T., Rodriguez-Aguayo, C., Zhang, D., Ram, P., et al. (2016) Direct upregulation of STAT3 by MicroRNA-551b-3p deregulates growth and metastasis of ovarian cancer. *Cell Rep.*, **15**, 1493–1504.
 73. Guo, H., Pu, M., Tai, Y., Chen, Y., Lu, H., Qiao, J., Wang, G., Chen, J., Qi, X., Huang, R., et al. (2021) Nuclear miR-30b-5p suppresses TFEB-mediated lysosomal biogenesis and autophagy. *Cell Death Differ.*, **28**, 320–336.
 74. Yan, K., An, T., Zhai, M., Huang, Y., Wang, Q., Wang, Y., Zhang, R., Wang, T., Liu, J., Zhang, Y., et al. (2019) Mitochondrial miR-762 regulates apoptosis and myocardial infarction by impairing ND2. *Cell Death. Dis.*, **10**, 500.
 75. Diener, C., Hart, M., Kehl, T., Becker-Dorison, A., Tanzer, T., Schub, D., Krammes, L., Sester, M., Keller, A., Unger, M., et al. (2023) Time-resolved RNA signatures of CD4+ T cells in Parkinson's disease. *Cell Death Discov.*, **9**, 18.
 76. Shepherd, D.L., Hathaway, Q.A., Pinti, M.V., Nichols, C.E., Durr, A.J., Sreekumar, S., Hughes, K.M., Stine, S.M., Martinez, I. and Hollander, J.M. (2017) Exploring the mitochondrial microRNA import pathway through polynucleotide phosphorylase (PNPase). *J. Mol. Cell Cardiol.*, **110**, 15–25.
 77. Vendramin, R., Marine, J.C. and Leucci, E. (2017) Non-coding RNAs: the dark side of nuclear-mitochondrial communication. *EMBO J.*, **36**, 1123–1133.
 78. Luo, Y., Na, Z. and Slavoff, S.A. (2018) P-Bodies: composition, properties, and functions. *Biochemistry*, **57**, 2424–2431.
 79. Pitchiaya, S., Mourao, M.D.A., Jaliha, A.P., Xiao, L., Jiang, X., Chinnaiyan, A.M., Schnell, S. and Walter, N.G. (2019) Dynamic recruitment of single RNAs to processing bodies depends on RNA functionality. *Mol. Cell*, **74**, 521–533.
 80. Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J. and Lotvall, J.O. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.*, **9**, 654–659.

81. Garcia-Martin,R., Wang,G., Brandao,B.B., Zanutto,T.M., Shah,S., Kumar Patel,S., Schilling,B. and Kahn,C.R. (2022) MicroRNA sequence codes for small extracellular vesicle release and cellular retention. *Nature*, **601**, 446–451.
82. Narayan,N., Morenos,L., Phipson,B., Willis,S.N., Brumatti,G., Eggers,S., Lalaoui,N., Brown,L.M., Kosasih,H.J., Bartolo,R.C., *et al.* (2017) Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia. *Leukemia*, **31**, 808–820.
83. Brown,B.D., Gentner,B., Cantore,A., Colleoni,S., Amendola,M., Zingale,A., Baccarini,A., Lazzari,G., Galli,C. and Naldini,L. (2007) Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. *Nat. Biotechnol.*, **25**, 1457–1467.
84. Sabi,R. and Tuller,T. (2019) Modelling and measuring intracellular competition for finite resources during gene expression. *J. R. Soc. Interface*, **16**, 20180887.
85. Grimm,D. (2011) The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression. *Silence*, **2**, 8.
86. Diener,C., Hart,M., Kehl,T., Rheinheimer,S., Ludwig,N., Krammes,L., Pawusch,S., Lenhof,K., Tanzer,T., Schub,D., *et al.* (2020) Quantitative and time-resolved miRNA pattern of early human T cell activation. *Nucleic Acids Res.*, **48**, 10164–10183.
87. de Rie,D., Abugessaisa,I., Alam,T., Arner,E., Arner,P., Ashoor,H., Astrom,G., Babina,M., Bertin,N., Burroughs,A.M., *et al.* (2017) An integrated expression atlas of miRNAs and their promoters in human and mouse. *Nat. Biotechnol.*, **35**, 872–878.
88. Denzler,R., McGeary,S.E., Title,A.C., Agarwal,V., Bartel,D.P. and Stoffel,M. (2016) Impact of MicroRNA levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression. *Mol. Cell*, **64**, 565–579.
89. Bosson,A.D., Zamudio,J.R. and Sharp,P.A. (2014) Endogenous miRNA and target concentrations determine susceptibility to potential ceRNA competition. *Mol. Cell*, **56**, 347–359.
90. Lai,X., Eberhardt,M., Schmitz,U. and Vera,J. (2019) Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer. *Nucleic Acids Res.*, **47**, 7753–7766.
91. Baccarini,A., Chauhan,H., Gardner,T.J., Jayaprakash,A.D., Sachidanandam,R. and Brown,B.D. (2011) Kinetic analysis reveals the fate of a microRNA following target regulation in mammalian cells. *Curr. Biol.*, **21**, 369–376.
92. Hutvagner,G. and Zamore,P.D. (2002) A microRNA in a multiple-turnover RNAi enzyme complex. *Science*, **297**, 2056–2060.
93. Haley,B. and Zamore,P.D. (2004) Kinetic analysis of the RNAi enzyme complex. *Nat. Struct. Mol. Biol.*, **11**, 599–606.
94. Su,H., Trombly,M.I., Chen,J. and Wang,X. (2009) Essential and overlapping functions for mammalian Argonautes in microRNA silencing. *Genes Dev.*, **23**, 304–317.
95. Nakanishi,K. (2022) Anatomy of four human Argonaute proteins. *Nucleic Acids Res.*, **50**, 6618–6638.
96. Voller,D., Linck,L., Bruckmann,A., Hauptmann,J., Deutzmann,R., Meister,G. and Bosserhoff,A.K. (2016) Argonaute family protein expression in normal tissue and cancer entities. *PLoS One*, **11**, e0161165.
97. Dueck,A., Ziegler,C., Eichner,A., Berezikov,E. and Meister,G. (2012) microRNAs associated with the different human Argonaute proteins. *Nucleic Acids Res.*, **40**, 9850–9862.
98. Turchinovich,A. and Burwinkel,B. (2012) Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. *RNA Biol.*, **9**, 1066–1075.
99. Burroughs,A.M., Ando,Y., de Hoon,M.J., Tomaru,Y., Suzuki,H., Hayashizaki,Y. and Daub,C.O. (2011) Deep-sequencing of human Argonaute-associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin. *RNA Biol.*, **8**, 158–177.
100. Liu,Q., Chen,X., Novak,M.K., Zhang,S. and Hu,W. (2021) Repressing Ago2 mRNA translation by Trim71 maintains pluripotency through inhibiting let-7 microRNAs. *eLife*, **10**, e66288.
101. Pawlica,P., Sheu-Gruttadauria,J., MacRae,I.J. and Steitz,J.A. (2019) How complementary targets expose the microRNA 3' end for tailing and trimming during target-directed microRNA degradation. *Cold Spring Harb. Symp. Quant. Biol.*, **84**, 179–183.
102. Park,J.H., Shin,S.Y. and Shin,C. (2017) Non-canonical targets destabilize microRNAs in human Argonautes. *Nucleic Acids Res.*, **45**, 1569–1583.
103. Ghini,F., Rubolino,C., Climent,M., Simeone,I., Marzi,M.J. and Nicassio,F. (2018) Endogenous transcripts control miRNA levels and activity in mammalian cells by target-directed miRNA degradation. *Nat. Commun.*, **9**, 3119.
104. Haas,G., Cetin,S., Messmer,M., Chane-Woon-Ming,B., Terenzi,O., Chicher,J., Kuhn,L., Hammann,P. and Pfeffer,S. (2016) Identification of factors involved in target RNA-directed microRNA degradation. *Nucleic Acids Res.*, **44**, 2873–2887.
105. Sheu-Gruttadauria,J., Pawlica,P., Klum,S.M., Wang,S., Yario,T.A., Schirle Oakdale,N.T., Steitz,J.A. and MacRae,I.J. (2019) Structural Basis for Target-Directed MicroRNA Degradation. *Mol. Cell*, **75**, 1243–1255.
106. Mukherji,S., Ebert,M.S., Zheng,G.X., Tsang,J.S., Sharp,P.A. and van Oudenaarden,A. (2011) MicroRNAs can generate thresholds in target gene expression. *Nat. Genet.*, **43**, 854–859.
107. Tay,Y., Rinn,J. and Pandolfi,P.P. (2014) The multilayered complexity of ceRNA crosstalk and competition. *Nature*, **505**, 344–352.
108. Thomson,D.W. and Dinger,M.E. (2016) Endogenous microRNA sponges: evidence and controversy. *Nat. Rev. Genet.*, **17**, 272–283.
109. Cremer,S., Michalik,K.M., Fischer,A., Pfisterer,L., Jae,N., Winter,C., Boon,R.A., Muhly-Reinholz,M., John,D., Uchida,S., *et al.* (2019) Hematopoietic deficiency of the long noncoding RNA MALAT1 promotes atherosclerosis and plaque inflammation. *Circulation*, **139**, 1320–1334.
110. Karagkouni,D., Karavangeli,A., Paraskevopoulou,M.D. and Hatzigeorgiou,A.G. (2021) Characterizing miRNA-lncRNA Interplay. *Methods Mol. Biol.*, **2372**, 243–262.
111. Hansen,T.B., Jensen,T.I., Clausen,B.H., Bramsen,J.B., Finsen,B., Damgaard,C.K. and Kjems,J. (2013) Natural RNA circles function as efficient microRNA sponges. *Nature*, **495**, 384–388.
112. Bosia,C., Pagnani,A. and Zecchina,R. (2013) Modelling competing endogenous RNA networks. *PLoS One*, **8**, e66609.
113. Kakumani,P.K. (2022) AGO-RBP crosstalk on target mRNAs: implications in miRNA-guided gene silencing and cancer. *Transl Oncol.*, **21**, 101434.
114. Kim,S., Kim,S., Chang,H.R., Kim,D., Park,J., Son,N., Park,J., Yoon,M., Chae,G., Kim,Y.K., *et al.* (2021) The regulatory impact of RNA-binding proteins on microRNA targeting. *Nat. Commun.*, **12**, 5057.
115. Li,Y., Estep,J.A. and Karginov,F.V. (2018) Transcriptome-wide identification and validation of interactions between the miRNA Machinery and HuR on mRNA targets. *J. Mol. Biol.*, **430**, 285–296.
116. Cottrell,K.A., Chaudhari,H.G., Cohen,B.A. and Djuranovic,S. (2018) PTRE-seq reveals mechanism and interactions of RNA binding proteins and miRNAs. *Nat. Commun.*, **9**, 301.
117. Nussbacher,J.K. and Yeo,G.W. (2018) Systematic discovery of RNA binding proteins that regulate MicroRNA levels. *Mol. Cell*, **69**, 1005–1016.
118. White,E.J., Matsangos,A.E. and Wilson,G.M. (2017) AUF1 regulation of coding and noncoding RNA. *Wiley Interdiscip. Rev. RNA*, **8**, <https://doi.org/10.1002/wrna.1393>.
119. Lambert,M.P., Terrone,S., Giraud,G., Benoit-Pilven,C., Cluet,D., Combaret,V., Mortreux,F., Auboeuf,D. and Bourgeois,C.F. (2018) The RNA helicase DDX17 controls the transcriptional activity of

- REST and the expression of proneural microRNAs in neuronal differentiation. *Nucleic Acids Res.*, **46**, 7686–7700.
120. Treiber,T, Treiber,N., Plessmann,U., Harlander,S., Daiss,J.L., Eichner,N., Lehmann,G., Schall,K., Urlaub,H. and Meister,G. (2017) A Compendium of RNA-Binding Proteins that Regulate MicroRNA Biogenesis. *Mol. Cell*, **66**, 270–284.
 121. Selbach,M., Schwanhausser,B., Thierfelder,N., Fang,Z., Khanin,R. and Rajewsky,N. (2008) Widespread changes in protein synthesis induced by microRNAs. *Nature*, **455**, 58–63.
 122. Kern,F., Krammes,L., Danz,K., Diener,C., Kehl,T., Kuchler,O., Fehlmann,T., Kahraman,M., Rheinheimer,S., Aparicio-Puerta,E., et al. (2021) Validation of human microRNA target pathways enables evaluation of target prediction tools. *Nucleic Acids Res.*, **49**, 127–144.
 123. Hart,M., Walch-Ruckheim,B., Krammes,L., Kehl,T., Rheinheimer,S., Tanzer,T., Glombitza,B., Sester,M., Lenhof,H.P., Keller,A., et al. (2019) miR-34a as hub of T cell regulation networks. *J. Immunother. Cancer*, **7**, 187.
 124. Kehl,T., Kern,F., Backes,C., Fehlmann,T., Stockel,D., Meese,E., Lenhof,H.P. and Keller,A. (2020) miRPathDB 2.0: a novel release of the miRNA Pathway Dictionary Database. *Nucleic Acids Res.*, **48**, D142–D147.
 125. Kern,F., Backes,C., Hirsch,P., Fehlmann,T., Hart,M., Meese,E. and Keller,A. (2020) What's the target: understanding two decades of in silico microRNA–target prediction. *Brief Bioinform.*, **21**, 1999–2010.
 126. Gerstner,N., Kehl,T., Lenhof,K., Muller,A., Mayer,C., Eckhart,L., Grammes,N.L., Diener,C., Hart,M., Hahn,O., et al. (2020) GeneTrail 3: advanced high-throughput enrichment analysis. *Nucleic Acids Res.*, **48**, W515–W520.
 127. Hart,M., Diener,C., Lunke,L., Rheinheimer,S., Krammes,L., Keller,A. and Meese,E. (2023) miR-34a-5p as molecular hub of pathomechanisms in Huntington's disease. *Mol. Med.*, **29**, 43.
 128. Khan,A.A., Betel,D., Miller,M.L., Sander,C., Leslie,C.S. and Marks,D.S. (2009) Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. *Nat. Biotechnol.*, **27**, 549–555.
 129. Patutina,O., Chiglintseva,D., Amirloo,B., Clarke,D., Gaponova,S., Vlassov,V., Bichenkova,E. and Zenkova,M. (2022) Bulge-forming miRNases cleave oncogenic miRNAs at the central loop region in a sequence-specific manner. *Int. J. Mol. Sci.*, **23**, 6562.
 130. Meng,L., Liu,C., Lu,J., Zhao,Q., Deng,S., Wang,G., Qiao,J., Zhang,C., Zhen,L., Lu,Y., et al. (2017) Small RNA zippers lock miRNA molecules and block miRNA function in mammalian cells. *Nat. Commun.*, **8**, 13964.
 131. Schaefer,M., Nabih,A., Spies,D., Hermes,V., Bodak,M., Wischnewski,H., Stalder,P., Ngondo,R.P., Liechti,L.A., Sajic,T., et al. (2022) Global and precise identification of functional miRNA targets in mESCs by integrative analysis. *EMBO Rep.*, **23**, e54762.
 132. Chang,H., Yi,B., Ma,R., Zhang,X., Zhao,H. and Xi,Y. (2016) CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. *Sci. Rep.*, **6**, 22312.
 133. Jeong,G., Lim,Y.H., Kim,N.J., Wee,G. and Kim,Y.K. (2017) Knockout of miR-221 and miR-222 reveals common and specific targets for paralogous miRNAs. *RNA Biol.*, **14**, 197–205.
 134. Menegatti,J., Nakel,J., Stepanov,Y.K., Caban,K.M., Ludwig,N., Nord,R., Pfizner,T., Yazdani,M., Vilimova,M., Kehl,T., et al. (2022) Changes of protein expression after CRISPR/Cas9 knockout of miRNA-142 in cell lines derived from diffuse large B-cell lymphoma. *Cancers (Basel)*, **14**, 5031.
 135. Murakami,K. and Miyagishi,M. (2014) Tiny masking locked nucleic acids effectively bind to mRNA and inhibit binding of microRNAs in relation to thermodynamic stability. *Biomed. Rep.*, **2**, 509–512.
 136. Sultana,S., Rozzi,A., Gasparello,J., Manicardi,A., Corradini,R., Papi,C., Finotti,A., Lampronti,I., Reali,E., Cabrini,G., et al. (2020) A peptide nucleic acid (PNA) masking the miR-145-5p binding site of the 3'UTR of the cystic fibrosis transmembrane conductance regulator (CFTR) mRNA enhances CFTR expression in Calu-3 cells. *Molecules*, **25**, 1677.
 137. Jin,H.Y., Gonzalez-Martin,A., Miletic,A.V., Lai,M., Knight,S., Sabouri-Ghomi,M., Head,S.R., Macauley,M.S., Rickert,R.C. and Xiao,C. (2015) Transfection of microRNA mimics should be used with caution. *Front. Genet.*, **6**, 340.
 138. Pitchiaya,S., Heinicke,L.A., Park,J.I., Cameron,E.L. and Walter,N.G. (2017) Resolving subcellular miRNA trafficking and turnover at single-molecule resolution. *Cell Rep.*, **19**, 630–642.
 139. Kingston,E.R. and Bartel,D.P. (2019) Global analyses of the dynamics of mammalian microRNA metabolism. *Genome Res.*, **29**, 1777–1790.
 140. Schwanhausser,B., Busse,D., Li,N., Dittmar,G., Schuchhardt,J., Wolf,J., Chen,W. and Selbach,M. (2011) Global quantification of mammalian gene expression control. *Nature*, **473**, 337–342.
 141. Huang,T.C., Pinto,S.M. and Pandey,A. (2013) Proteomics for understanding miRNA biology. *Proteomics*, **13**, 558–567.
 142. Wen,J., Leucci,E., Vendramin,R., Kauppinen,S., Lund,A.H., Krogh,A. and Parker,B.J. (2015) Transcriptome dynamics of the microRNA inhibition response. *Nucleic Acids Res.*, **43**, 6207–6221.
 143. Sindhu,K.J., Venkatesan,N. and Karunakaran,D. (2021) MicroRNA interactome multiomics characterization for cancer research and personalized medicine: an expert review. *OMICS*, **25**, 545–566.
 144. Seo,J., Jin,D., Choi,C.H. and Lee,H. (2017) Integration of MicroRNA, mRNA, and protein expression data for the identification of cancer-related MicroRNAs. *PLoS One*, **12**, e0168412.
 145. Git,A., Dvinge,H., Salmon-Divon,M., Osborne,M., Kutter,C., Hadfield,J., Bertone,P. and Caldas,C. (2010) Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. *RNA*, **16**, 991–1006.
 146. Guo,H., Ingolia,N.T., Weissman,J.S. and Bartel,D.P. (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. *Nature*, **466**, 835–840.
 147. Martinez-Sanchez,A. and Murphy,C.L. (2013) MicroRNA target identification-experimental approaches. *Biology (Basel)*, **2**, 189–205.
 148. Thomson,D.W., Bracken,C.P. and Goodall,G.J. (2011) Experimental strategies for microRNA target identification. *Nucleic Acids Res.*, **39**, 6845–6853.
 149. Filip,R., Desrochers,G.F., Lefebvre,D.M., Reed,A., Singaravelu,R., Cravatt,B.F. and Pezacki,J.P. (2021) Profiling of MicroRNA targets using activity-based protein profiling: linking enzyme activity to microRNA-185 function. *Cell Chem. Biol.*, **28**, 202–212.
 150. O'Sullivan,F., Keenan,J., Aherne,S., O'Neill,F., Clarke,C., Henry,M., Meleady,P., Breen,L., Barron,N., Clynes,M., et al. (2017) Parallel mRNA, proteomics and miRNA expression analysis in cell line models of the intestine. *World J. Gastroenterol.*, **23**, 7369–7386.
 151. Sedaghat,N., Fathy,M., Modarressi,M.H. and Shojaie,A. (2018) Combining supervised and unsupervised learning for improved miRNA target prediction. *IEEE/ACM Trans. Comput. Biol. Bioinform.*, **15**, 1594–1604.
 152. Rokavec,M., Huang,Z. and Hermeking,H. (2023) Meta-analysis of miR-34 target mRNAs using an integrative online application. *Comput. Struct. Biotechnol. J.*, **21**, 267–274.
 153. Wang,Y.P. and Li,K.B. (2009) Correlation of expression profiles between microRNAs and mRNA targets using NCI-60 data. *Bmc Genomics [Electronic Resource]*, **10**, 218.
 154. Abel,Y. and Rederstorff,M. (2021) Gene reporter assays to study miRNA function. *Methods Mol. Biol.*, **2300**, 119–131.
 155. Chou,C.H., Shrestha,S., Yang,C.D., Chang,N.W., Lin,Y.L., Liao,K.W., Huang,W.C., Sun,T.H., Tu,S.J., Lee,W.H., et al. (2018) miRTarBase update 2018: a resource for experimentally

- validated microRNA–target interactions. *Nucleic Acids Res.*, **46**, D296–D302.
156. Kuhn, D.E., Martin, M.M., Feldman, D.S., Terry, A.V. Jr, Nuovo, G.J. and Elton, T.S. (2008) Experimental validation of miRNA targets. *Methods*, **44**, 47–54.
 157. Riolo, G., Cantara, S., Marzocchi, C. and Ricci, C. (2020) miRNA targets: from prediction tools to experimental validation. *Methods Protoc.*, **4**, 1.
 158. Hu, X., Zou, Q., Yao, L. and Yang, X. (2022) Survey of the binding preferences of RNA-binding proteins to RNA editing events. *Genome Biol.*, **23**, 169.
 159. Arnold, M., Ellwanger, D.C., Hartsperger, M.L., Pfeufer, A. and Stumpflen, V. (2012) Cis-acting polymorphisms affect complex traits through modifications of microRNA regulation pathways. *PLoS One*, **7**, e36694.
 160. Bhattacharya, A. and Cui, Y. (2017) Systematic prediction of the impacts of mutations in MicroRNA seed sequences. *J. Integr. Bioinform.*, **14**, 20170001.
 161. Donnelly, B.F., Yang, B., Grimme, A.L., Vieux, K.F., Liu, C.Y., Zhou, L. and McJunkin, K. (2022) The developmentally timed decay of an essential microRNA family is seed-sequence dependent. *Cell Rep.*, **40**, 111154.
 162. Yang, B., Schwartz, M. and McJunkin, K. (2020) In vivo CRISPR screening for phenotypic targets of the mir-35-42 family in *C. elegans*. *Genes Dev.*, **34**, 1227–1238.
 163. Patel, R.K., West, J.D., Jiang, Y., Fogarty, E.A. and Grimson, A. (2020) Robust partitioning of microRNA targets from downstream regulatory changes. *Nucleic Acids Res.*, **48**, 9724–9746.
 164. Kazmierczak, D. and Hydbring, P. (2021) Construction of a full-length 3'UTR reporter system for identification of cell-cycle regulating MicroRNAs. *Methods Mol. Biol.*, **2329**, 81–94.
 165. Wolter, J.M., Kotagama, K., Pierre-Bez, A.C., Firago, M. and Mangone, M. (2014) 3'LIFE: a functional assay to detect miRNA targets in high-throughput. *Nucleic Acids Res.*, **42**, e132.
 166. Brustikova, K., Sedlak, D., Kubikova, J., Skuta, C., Solcova, K., Malik, R., Bartunek, P. and Svoboda, P. (2018) Cell-based reporter system for high-throughput screening of MicroRNA pathway inhibitors and its limitations. *Front. Genet.*, **9**, 45.
 167. Beitzinger, M., Peters, L., Zhu, J.Y., Kremmer, E. and Meister, G. (2007) Identification of human microRNA targets from isolated argonaute protein complexes. *RNA Biol.*, **4**, 76–84.
 168. Chi, S.W., Zang, J.B., Mele, A. and Darnell, R.B. (2009) Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. *Nature*, **460**, 479–486.
 169. Helwak, A., Kudla, G., Dudnakova, T. and Tollervey, D. (2013) Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. *Cell*, **153**, 654–665.
 170. Kudla, G., Granneman, S., Hahn, D., Beggs, J.D. and Tollervey, D. (2011) Cross-linking, ligation, and sequencing of hybrids reveals RNA-RNA interactions in yeast. *Proc. Natl. Acad. Sci. USA*, **108**, 10010–10015.
 171. Petri, R. and Jakobsson, J. (2018) Identifying miRNA targets using AGO-RIPseq. *Methods Mol. Biol.*, **1720**, 131–140.
 172. Tichy, D., Pickl, J.M.A., Benner, A. and Sultmann, H. (2018) Experimental design and data analysis of Ago-RIP-Seq experiments for the identification of microRNA targets. *Brief. Bioinform.*, **19**, 918–929.
 173. Xun, Y., Tang, Y., Hu, L., Xiao, H., Long, S., Gong, M., Wei, C., Wei, K. and Xiang, S. (2019) Purification and Identification of miRNA Target Sites in Genome Using DNA Affinity Precipitation. *Front. Genet.*, **10**, 778.
 174. Hafner, M., Lianoglou, S., Tuschl, T. and Betel, D. (2012) Genome-wide identification of miRNA targets by PAR-CLIP. *Methods*, **58**, 94–105.
 175. Liu, C., Mallick, B., Long, D., Rennie, W.A., Wolenc, A., Carmack, C.S. and Ding, Y. (2013) CLIP-based prediction of mammalian microRNA binding sites. *Nucleic Acids Res.*, **41**, e138.
 176. Kaur, G. and Dufour, J.M. (2012) Cell lines: valuable tools or useless artifacts. *Spermatogenesis*, **2**, 1–5.
 177. Li, X., Pritykin, Y., Concepcion, C.P., Lu, Y., La Rocca, G., Zhang, M., King, B., Cook, P.J., Au, Y.W., Popow, O., et al. (2020) High-resolution in vivo identification of miRNA targets by halo-enhanced Ago2 pull-down. *Mol. Cell*, **79**, 167–179.
 178. Chu, Y., Kilikevicius, A., Liu, J., Johnson, K.C., Yokota, S. and Corey, D.R. (2020) Argonaute binding within 3'-untranslated regions poorly predicts gene repression. *Nucleic Acids Res.*, **48**, 7439–7453.
 179. Reinkens, T., Stalke, A., Hüge, N., Vajen, B., Eilers, M., Schaffer, V., Dittrich-Breiholz, O., Schlegelberger, B., Illig, T. and Skawran, B. (2022) Ago-RIP sequencing identifies new MicroRNA-449a-5p target genes increasing sorafenib efficacy in hepatocellular carcinoma. *J. Cancer*, **13**, 62–75.
 180. Androsavich, J.R. (2017) Competitive Argonaute-based RNA immunoprecipitation for investigation of transcriptomic response to anti-miR. *Methods Mol. Biol.*, **1517**, 91–102.